ECSP077372A - Antagonistas del receptor de trombina - Google Patents
Antagonistas del receptor de trombinaInfo
- Publication number
- ECSP077372A ECSP077372A EC2007007372A ECSP077372A ECSP077372A EC SP077372 A ECSP077372 A EC SP077372A EC 2007007372 A EC2007007372 A EC 2007007372A EC SP077372 A ECSP077372 A EC SP077372A EC SP077372 A ECSP077372 A EC SP077372A
- Authority
- EC
- Ecuador
- Prior art keywords
- bond
- thrombine
- double bond
- receiver antagonists
- tricyclics
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 229940125692 cardiovascular agent Drugs 0.000 abstract 1
- 239000002327 cardiovascular agent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000010235 heart cancer Diseases 0.000 abstract 1
- 208000024348 heart neoplasm Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
Abstract
Se describen tricíclicos sustituidos con heterocíclicos de la fórmula o una sal o solvato de dicho compuesto, isómero o mezcla racémica donde representa un doble enlace optativo, la línea de puntos es optativamente un enlace o falta de enlace, para dar lugar a un doble enlace o un enlace simple, según lo permita el requerimiento de la valencia y donde A, B, G, M, X, J, n, Het, R3, R10, R11, R32 y R33 se definen en la presente y el resto de los sustituyentes son como se los definiera en la memoria descriptiva, así como composiciones farmacéuticas que los contienen y un método para el tratamiento de enfermedades asociadas con la trombosis, aterosclerosis, restenosis, hipertensión, angina de pecho, arritmia, insuficiencia cardiaca y cáncer mediante la administración de dichos compuestos. También se reivindica una terapia combinatoria con otros agentes cardiovasculares.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61751404P | 2004-10-08 | 2004-10-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP077372A true ECSP077372A (es) | 2007-05-30 |
Family
ID=36061549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2007007372A ECSP077372A (es) | 2004-10-08 | 2007-04-04 | Antagonistas del receptor de trombina |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7488752B2 (es) |
| EP (2) | EP2075250B1 (es) |
| JP (1) | JP2008515899A (es) |
| KR (1) | KR20070101216A (es) |
| CN (1) | CN101072772A (es) |
| AR (1) | AR054611A1 (es) |
| AU (1) | AU2005294490A1 (es) |
| BR (1) | BRPI0518159A (es) |
| CA (1) | CA2582639A1 (es) |
| EC (1) | ECSP077372A (es) |
| IL (1) | IL182355A0 (es) |
| MX (1) | MX2007004197A (es) |
| NO (1) | NO20072344L (es) |
| RU (1) | RU2408594C2 (es) |
| TW (1) | TW200626584A (es) |
| WO (1) | WO2006041872A2 (es) |
| ZA (1) | ZA200702790B (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040192753A1 (en) * | 2000-06-15 | 2004-09-30 | Samuel Chackalamannil | Methods of use of thrombin receptor antagonists |
| AR060354A1 (es) * | 2006-04-06 | 2008-06-11 | Schering Corp | Terapias de combinacion antagonistas receptor trombina (tra) |
| CA2667082A1 (en) * | 2006-10-04 | 2008-04-10 | Schering Corporation | Bicyclic and tricyclic derivatives as thrombin receptor antagonists |
| US8227412B2 (en) * | 2007-03-29 | 2012-07-24 | Tsopanoglou Nikos E | Bioactive parstatin peptides and methods of use |
| US20090022729A1 (en) * | 2007-04-13 | 2009-01-22 | Nigel Mackman | Methods and compositions for treating cardiac dysfunctions |
| ES2527535T3 (es) | 2010-04-16 | 2015-01-26 | Sanofi | Piridil-vinil-pirazolo-quinolinas como inhibidores de PAR1 |
| PL2558465T3 (pl) | 2010-04-16 | 2015-05-29 | Sanofi Sa | Trycykliczne pirydylo-winylo-pirole jako inhibitory receptora aktywowanego proteazą 1 (PAR1) |
| EP2701719A4 (en) * | 2011-04-28 | 2015-04-22 | Claire Mitchell | METHOD FOR TREATING MACULAR OBGENATION BY MODULATION OF P2Y12 OR P2X7 RECEPTORS |
| WO2013134012A1 (en) | 2012-03-06 | 2013-09-12 | Merck Sharp & Dohme Corp. | Preparation and use of bicyclic himbacine derivatives as par-receptor antagonists |
| PT2855456T (pt) * | 2012-05-04 | 2017-07-10 | Novartis Ag | Moduladores da via do complemento e usos dos mesmos |
| US9056874B2 (en) | 2012-05-04 | 2015-06-16 | Novartis Ag | Complement pathway modulators and uses thereof |
| US9475806B2 (en) | 2013-03-14 | 2016-10-25 | Novartis Ag | Complement factor B inhibitors and uses there of |
| WO2015026693A1 (en) | 2013-08-22 | 2015-02-26 | Merck Sharp & Dohme Corp. | 7a-amide substituted-6,6-difluoro bicyclic himbacine derivatives |
| WO2015026686A1 (en) | 2013-08-22 | 2015-02-26 | Merck Sharp & Dohme Corp. | 3'-pyridyl substituted- 6,6-difluoro bicyclic himbacine derivatives |
| EP3035930A4 (en) | 2013-08-22 | 2017-03-08 | Merck Sharp & Dohme Corp. | 7a-heterocycle substituted- 6, 6-difluoro bicyclic himbacine derivatives |
| CN104447927A (zh) * | 2013-09-13 | 2015-03-25 | 天津市汉康医药生物技术有限公司 | 坎格雷洛一水合物晶体及其制备方法 |
| CN104447928A (zh) * | 2013-09-13 | 2015-03-25 | 天津市汉康医药生物技术有限公司 | 坎格雷洛二水化合物 |
| EP3089963A1 (en) * | 2013-10-30 | 2016-11-09 | Novartis AG | 2-benzyl-benzimidazole complement factor b inhibitors and uses thereof |
| WO2016058144A1 (en) * | 2014-10-15 | 2016-04-21 | Merck Sharp & Dohme Corp. | Preparation and use of cyclic sulfonamide derivatives as par-1 receptor antagonists |
| CN105732595B (zh) * | 2015-12-22 | 2018-08-28 | 山东大学 | 基于萜类衍生物的par-1抑制剂及其制备方法和在治疗血栓性疾病中的用途 |
| CN107304199B (zh) * | 2016-04-22 | 2021-09-21 | 江苏天士力帝益药业有限公司 | 一种新的喜巴辛类似物及其在医药中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL106197A (en) | 1992-07-30 | 1999-11-30 | Cor Therapeutics Inc | Agagonists for the rhombin receptors and pharmaceutical preparations containing them |
| NZ504218A (en) * | 1997-11-25 | 2002-04-26 | Schering Corp | Thrombin receptor antagonists |
| US6063847A (en) | 1997-11-25 | 2000-05-16 | Schering Corporation | Thrombin receptor antagonists |
| US7488742B2 (en) * | 2000-06-15 | 2009-02-10 | Schering Corporation | Thrombin receptor antagonists |
| US6645987B2 (en) * | 2000-06-15 | 2003-11-11 | Schering Corporation | Nor-seco himbacine derivatives useful as thrombin receptor antagonists |
| WO2003033501A1 (en) | 2001-10-18 | 2003-04-24 | Schering Corporation | Himbacine analogues as thrombin receptor antagonists |
| US7086034B2 (en) * | 2002-06-28 | 2006-08-01 | Canon Kabushiki Kaisha | Method, program, and storage medium for acquiring logs |
-
2005
- 2005-10-05 CN CNA2005800422977A patent/CN101072772A/zh active Pending
- 2005-10-05 MX MX2007004197A patent/MX2007004197A/es active IP Right Grant
- 2005-10-05 EP EP09156735.4A patent/EP2075250B1/en not_active Expired - Lifetime
- 2005-10-05 BR BRPI0518159-3A patent/BRPI0518159A/pt not_active IP Right Cessation
- 2005-10-05 RU RU2007116850/04A patent/RU2408594C2/ru not_active IP Right Cessation
- 2005-10-05 EP EP05802841A patent/EP1802609A2/en not_active Withdrawn
- 2005-10-05 WO PCT/US2005/035745 patent/WO2006041872A2/en not_active Ceased
- 2005-10-05 AU AU2005294490A patent/AU2005294490A1/en not_active Abandoned
- 2005-10-05 JP JP2007535765A patent/JP2008515899A/ja active Pending
- 2005-10-05 US US11/243,708 patent/US7488752B2/en active Active
- 2005-10-05 CA CA002582639A patent/CA2582639A1/en not_active Abandoned
- 2005-10-05 KR KR1020077007897A patent/KR20070101216A/ko not_active Ceased
- 2005-10-06 AR ARP050104221A patent/AR054611A1/es not_active Application Discontinuation
- 2005-10-06 TW TW094135027A patent/TW200626584A/zh unknown
-
2007
- 2007-04-01 IL IL182355A patent/IL182355A0/en unknown
- 2007-04-03 ZA ZA200702790A patent/ZA200702790B/xx unknown
- 2007-04-04 EC EC2007007372A patent/ECSP077372A/es unknown
- 2007-05-07 NO NO20072344A patent/NO20072344L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2075250B1 (en) | 2015-03-04 |
| EP1802609A2 (en) | 2007-07-04 |
| EP2075250A2 (en) | 2009-07-01 |
| CA2582639A1 (en) | 2006-04-20 |
| ZA200702790B (en) | 2008-09-25 |
| AU2005294490A1 (en) | 2006-04-20 |
| RU2408594C2 (ru) | 2011-01-10 |
| IL182355A0 (en) | 2007-07-24 |
| WO2006041872A2 (en) | 2006-04-20 |
| US7488752B2 (en) | 2009-02-10 |
| EP2075250A3 (en) | 2009-10-14 |
| NO20072344L (no) | 2007-07-04 |
| KR20070101216A (ko) | 2007-10-16 |
| US20060079684A1 (en) | 2006-04-13 |
| CN101072772A (zh) | 2007-11-14 |
| WO2006041872A3 (en) | 2007-01-04 |
| AR054611A1 (es) | 2007-07-04 |
| TW200626584A (en) | 2006-08-01 |
| MX2007004197A (es) | 2007-06-15 |
| RU2007116850A (ru) | 2008-11-20 |
| JP2008515899A (ja) | 2008-05-15 |
| BRPI0518159A (pt) | 2008-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP077372A (es) | Antagonistas del receptor de trombina | |
| CO6531452A2 (es) | Piperidinas sustituidas que aumentan la actividad de p53 y sus usos | |
| MX2009003761A (es) | Derivados biciclicos y triciclicos como antagonistas del receptor de trombina. | |
| UY31050A1 (es) | Antagonistas de trpv1 y usos de los mismos | |
| UY31127A1 (es) | Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841 | |
| CY1109369T1 (el) | Υποκατεστημενες πυρρολοπυριδινες, οι ενωσεις που τις περιεχουν, η διαδικασια παρασκευης τους και η χρηση τους | |
| PE20190811A1 (es) | Derivados de pirazolopirimidinas como inhibidor de quinasa | |
| CR20110099A (es) | Pirrolidina-2-carboxamidas sustituidas | |
| TW200718697A (en) | Spirocyclic thrombin receptor antagonists | |
| CR11089A (es) | Derivados de carboxamida imidazolidina como modulares de p2x7 | |
| CR20120410A (es) | Pirrolidina-2-carboxamidas sustituidas | |
| ECSP17007208A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| ECSP088484A (es) | Derivados de quinazolina espirocíclicos como inhibidores de pde7 | |
| CY1123880T1 (el) | Καινοτομοι 5-ητ2 ανταγωνιστες | |
| MX376743B (es) | Síntesis de lactonas de ácido resorcílico útiles como agentes terapéuticos | |
| PA8589601A1 (es) | Derivados de indazol como antagonistas del crf | |
| CL2020000944A1 (es) | Compuestos bicíclicos y métodos de utilización de los mismos. | |
| CR20110294A (es) | Piperidina espiro pirrolidinona y piperidinona sustituidas, su preparación y su uso terapéutico | |
| UY28906A1 (es) | Derivados de pirimidina que son antagonistas del receptor vitronectina | |
| PA8589801A1 (es) | Aminoalcoxiindoles | |
| AR063095A1 (es) | Antagonistas del receptor de trombina basados en la unidad triciclica modificada de himbacina | |
| CO6341557A2 (es) | Derivados nitrogenados de la pancratistatina | |
| UY31854A (es) | Derivados sustituidos de 3-oxo-isoindolin-1- carboxamidas n-sustituidas y aplicaciones | |
| TW200732330A (en) | Oxazoloisoquinoline derivatives as thrombin receptor antagonists | |
| UY29134A1 (es) | Sulfonamidas sustituidas por derivados de bencimidazol, composiciones que la contienen, procedimiento de preparacion y aplicaciones |